Mr. Andre Larente reports

DIAGNOS ANNOUNCES AMENDMENT TO CONVERTIBLE DEBENTURES

Diagnos Inc. intends to extend the maturity date for $300,000 of unsecured convertible debentures issued as part of a private placement of units initially announced on May 18, 2023. The maturity date, initially set for May 18, 2025, is being extended to May 18, 2026.

All other provisions of the debentures will remain unchanged and fully in effect during the extension period.

One insider of the corporation is the beneficial owner of two debentures for an aggregate nominal value of $100,000. Assuming the (i) conversion of the debentures and (ii) exercise of all outstanding securities, the insider would own 3,446,056 common shares of the corporation, representing 3.35 per cent of the total issued common shares, on a partially diluted basis. The insider is considered a related party of the corporation within the meaning of Multilateral Instrument 61-101, Protection of Minority Security Holders in Special Transactions. The amendment is exempt from the valuation requirement and the minority approval requirement prescribed in MI 61-101, based on sections 5.5(a) and 5.7(1)(a), as the fair market value of the related party participation in the amendment to convertible debentures does not exceed 25 per cent of the corporation's current market capitalization. The board of directors of the corporation has reviewed and approved the amendment to ensure that it was in the best interest of Diagnos and its shareholders.

The amendment remains subject to the TSX Venture Exchange acceptance, as well as the execution of formal documentation.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging artificial intelligence, Diagnos aims to provide more information to health care clinicians to enhance diagnostic accuracy, streamline workflows and improve patient outcomes on a global scale.

We seek Safe Harbor.